Today’s stock pick update – Open Now

[Learn More]( [You Could Make $300 to $1100 Per Contract With This Simple Trade]( Imagine getting really good at mastering just ONE simple trade. A trade that appears like clockwork between 9:30-10:45am on most trading days. This free step-by-step guide, by options expert, Dave Acquino, shows you how to spot and take these trades so you can walk away with daily profits!(Ad) [CLICK HERE for instant access.]( Macy’s Shares Are Down After It Says It’s Cutting 3,900 Corporate Jobs Major bank stocks traded higher this morning after officials from the Federal Deposit Insurance Commission [said]( on a call that they are loosening the restrictions from the Volker Rule, allowing banks to more easily make large investments into venture capital and similar funds. The reversal could free up an estimated $40 billion for Wall Street banks,... [Read More]( Vaxart Inc (NASDAQ: [VXRT]( Vaxart shares are up 43% this morning after the biotech announced that it has signed a Memorandum of Understanding with Attwill Medical Solutions Sterilflow, LP (AMS) affirming the parties’ intent to establish AMS as a resource for lyophilization development and large scale manufacturing including tableting and enteric coating for Vaxart’s oral COVID-... [Read More]( [Does MAN’s value proposition hold in an economic recession?]( ManpowerGroup Inc. ([MAN]( is one of the largest providers of workforce solutions and services, with operations that span the globe. So far, the most dramatically affected industries have been those that rely the most on face-to-face interactions, such as restaurants, theaters, and so on. On the other hand, the pandemic has also forced much of corporate America to shift to a work-at-home model, which has managed to keep employment numbers for highly skilled te... [Read More]( Featured Stock [Genprex, Inc. (GNPX) – Buy Price: $4.00 or better]( Genprex, Inc. operates as a clinical-stage gene therapy company. The company engages in developing technologies for cancer patients based upon a proprietary technology platform. Its platform technologies are designed to administer cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. [Read More]( Other Top Stories - [EU to help resolve Cyprus-Turkey maritime border wrangle]( - [With Climate Pledge Arena, Amazon puts promise in lights]( - [Judge shuts down energy pipeline in Michigan's Great Lakes]( - [Judge shuts down energy pipeline in Michigan’s Great Lakes after damage to key support piece]( - [Texas puts reopening on 'pause' as virus cases soar]( Trend Following Picks - [Genprex, Inc. (GNPX) – Buy Price: $4.00 or better]( - [IVERIC bio, Inc. (ISEE) – Buy Price: $6.25 or better]( - [Gerdau S.A. (GGB) – Buy Price: $3.25 or better]( - [Agenus Inc. (AGEN) – Buy Price: $4.25 or better]( - [Coffee Holding Co., Inc. (JVA) – Buy Price: $3.75 or better]( [All Picks]( Reversal Picks - [Arvinas, Inc. (ARVN) Buy Target $36.90 Sell Target $45.42]( - [TETRA Technologies, Inc. (TTI) Buy Target $0.53 Sell Target $0.63]( - [CytomX Therapeutics, Inc. (CTMX) Buy Target $10.43 Sell Target $12.34]( - [Aytu BioScience, Inc. (AYTU) Buy Target $1.64 Sell Target $1.82]( - [Iovance Biotherapeutics, Inc. (IOVA) Buy Target $31.63 – Sell Target $36.42]( [All Picks]( Low Price Stock Picks - [Citius Pharmaceuticals, Inc. (CTXR)]( - [Civeo Corporation (CVEO)]( - [Gold Standard Ventures Corp (GSV)]( - [Vista Gold Corp. (VGZ)]( - [Tyme Technologies, Inc. (TYME)]( [All Picks]( Already subscribed to our premium service? [Click here to Login.]( Not a TradersPro subscriber yet? [Learn More About TradersPro Here - Learn The # 1 Key To Successful Stock Investing Profits]( --------------------------------------------------------------- This email was sent to {EMAIL} by Investiv, LLC 265 N. Main | Ste. D #283 | Kaysville | UT | 84037 [Forward to a friend]( | [Unsubscribe]( or [Mange which emails you get from TradersPro]( Disclaimers Investing is Inherently Risky There are risks inherent in all investments, which may make such investments unsuitable for certain persons. These include, for example, economic, political, currency exchange, rate fluctuations, and limited availability of information on international securities. You may lose all of your money trading and investing. Do NOT enter any trade without fully understanding the worst-case scenarios of that trade. And do NOT trade with money you cannot afford to lose. Past performance of an investment is not necessarily indicative of its future results. No assurance can be given that any implied recommendation will be profitable or will not be subject to losses. Hypothetical Results Are Reported Results and examples used in the Company’s advertisements, books, videos, websites, and other media—including on the Site and the Network—are, in some cases, based on hypothetical (simulated) trades. Plainly speaking, these trades were not actually executed. Hypothetical performance results have certain limitations. Unlike an actual performance record, hypothetical results do not represent actual trading. Also, since the trades have not been executed, the hypothetical results may have under-or-over compensation for the impact, if any, of certain market factors, such as lack of liquidity. Hypothetical trading programs generally are also subject to the fact that they are designed with the benefit of hindsight. Hypothetical results also do not account for commissions or slippage. The Company’s simulations assume purchase and sale prices believed to be attainable. Yet traders are going to be getting into trades at different times and using various exit approaches, which may result in different pricing and outcomes. You may or may not receive the best available price on the purchase or the sale of a position in actual trading. Information provided by the Company is not investment advice. The Company is not a registered investment adviser, stock broker, or brokerage. You agree that the Company does not represent, warrant, or take responsibility that any account will or is likely to achieve profit or losses similar to those shown. Examples published by the Company are selected for illustrative purposes only. They are not typical and do not represent the typical results of all stocks within the Company’s software or its individual scans and searches. No independent party has audited any hypothetical performance contained at this Web site, nor has any independent party undertaken to confirm that they reflect the trading method under the assumptions or conditions specified. Offers Disinterested Commentary and Analysis The Company does not receive any form of payment or other compensation for publishing information, news, research, or any other material concerning specific securities on the Network that is intended to affect or influence the value of securities. The Company, and its personnel, do not engage in front-running of recommendations and do not trade against one’s own recommendations. The Company and its management may benefit from an increase or decrease in the share prices of the profiled companies, and/or may have other actual or potential conflicts of interest. If a particular security featured in a newsletter publication is concurrently owned by the Company in its corporate brokerage account, or in any of the individual accounts of the Company’s principals or analysts / writers, that fact will be disclosed. The Company, its principals, analysts and writers may choose to purchase a security or derivative featured in one of its newsletter publications, but typically will wait three (3) trading days from the date of publication before initiating said purchase. [Disclaimers, Terms & Conditions]( | [Privacy Policy]( Copyright © 2019